{"id":233663,"date":"2026-03-19T19:02:24","date_gmt":"2026-03-20T00:02:24","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/03\/the-moment-a-new-cancer-treatment-met-its-first-patient"},"modified":"2026-03-19T19:02:24","modified_gmt":"2026-03-20T00:02:24","slug":"the-moment-a-new-cancer-treatment-met-its-first-patient","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/03\/the-moment-a-new-cancer-treatment-met-its-first-patient","title":{"rendered":"The Moment a New Cancer Treatment Met Its First Patient"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/the-moment-a-new-cancer-treatment-met-its-first-patient.jpg\"><\/a><\/p>\n<p>In the early stages of the HMBD-001 clinical trial, Ingram and his team focused primarily on the drug\u2019s safety and tolerability, as well as building a dataset that could support clear decisions about where the medicine could help patients most. In early clinical evaluations, HMBD-001 has shown encouraging signals, and the trials have expanded beyond London to multiple international sites.<\/p>\n<p>In January, Ingram and team announced that the first patient had been dosed with HMBD-501. The first clinical trial for HMBD-501 is currently recruiting cancer patients in the United States and Australia. Soon, more patients will begin receiving HMBD-501 as it enters clinical testing.<\/p>\n<p>The expansion of HMBD-501 clinical trials is a chance to learn more about one of biology\u2019s biggest problems and how to solve it. But it wouldn\u2019t have been possible if the Hummingbird Bioscience team hadn\u2019t asked the important questions in their lab in Singapore.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the early stages of the HMBD-001 clinical trial, Ingram and his team focused primarily on the drug\u2019s safety and tolerability, as well as building a dataset that could support clear decisions about where the medicine could help patients most. In early clinical evaluations, HMBD-001 has shown encouraging signals, and the trials have expanded beyond [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-233663","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/233663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=233663"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/233663\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=233663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=233663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=233663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}